Alzheimer's disease, enzyme targets and drug discovery struggles: From natural products to drug prototypes

Ageing Research Reviews

Volumn 15, Issue 1, 2014, Pages 116-145

  Silva, Tiago ^a   Reis, Joana ^a   Teixeira, José ^a   Borges, Fernanda ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Acetylcholinesterase and inhibitors; Alzheimer's disease; Autophagy enhancers; Caspases and inhibitors; Glycogen synthase kinase 3 and inhibitors; Sirtuins and inhibitors; Synaptogenesis enhancers; and secretases and inhibitors

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; ACETYLCHOLINESTERASE; ALPHA SECRETASE; AVAGACESTAT; BEGACESTAT; BERBERINE; BETA SECRETASE; BETA SECRETASE INHIBITOR; BRYOSTATIN 1; CASPASE; CTS 21166; DONEPEZIL; ENZYME; ENZYME ACTIVATOR; ENZYME INHIBITOR; ETAZOLATE; GALANTAMINE; GAMMA SECRETASE; GRL 8234; GSK 188909; HUPERZINE A; HUPERZINE B; KMI 429; MINOCYCLINE; OM 992; PF 3084014; RIVASTIGMINE; SEMAGACESTAT; SIRTUIN 2; TACRINE; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT;

ALZHEIMER DISEASE; ANTIDIABETIC ACTIVITY; ANTIMICROBIAL ACTIVITY; BERBERIS; BLOOD BRAIN BARRIER; CHOLINERGIC TRANSMISSION; COPTIS CHINENSIS; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SPECIFICITY; HERB; HUMAN; HUPERZIA; HYDRASTIS; IMMUNOMODULATION; NONHUMAN; REVIEW; TORPEDO CALIFORNICA; X RAY CRYSTALLOGRAPHY; AGED; DRUG DEVELOPMENT; ENZYMOLOGY;

AGED; ALZHEIMER DISEASE; BIOLOGICAL PRODUCTS; DRUG DISCOVERY; HUMANS;

EID: 84899683262     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2014.03.008     Document Type: Review

References (240)

1. Akhtar M., Bharatam P.V. 3D-QSAR and molecular docking studies on 3-anilino-4-arylmaleimide derivatives as glycogen synthase kinase-3beta inhibitors. Chem. Biol. Drug Des. 2012, 79(4):560-571.
2. Akhtar M.W., Raingo J., et al. Histone deacetylases 1 and 2 form a developmental switch that controls excitatory synapse maturation and function. J. Neurosci. 2009, 29(25):8288-8297.
3. Aliev G., Obrenovich M.E., et al. Antioxidant therapy in Alzheimer's disease: theory and practice. Mini Rev. Med. Chem. 2008, 8(13):1395-1406.
4. Amar S., Belmaker R.H., et al. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases. Curr. Pharm. Des. 2011, 17(22):2264-2277.
5. Asai M., Hattori C., et al. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J. Neurochem. 2006, 96(2):533-540.
6. Avila J., Hernandez F. GSK-3 inhibitors for Alzheimer's disease. Expert Rev. Neurother. 2007, 7(11):1527-1533.
7. Bai D.L., Tang X.C., et al. Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Curr. Med. Chem. 2000, 7(3):355-374.
8. Banerjee R., Beal M.F., et al. Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends Neurosci. 2010, 33(12):541-549.
9. Berger Z., Ravikumar B., et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 2006, 15(3):433-442.
10. Berr C., Wancata J., et al. Prevalence of dementia in the elderly in Europe. Eur. Neuropsychopharmacol. 2005, 15(4):463-471.
11. Bezprozvanny I., Mattson M.P. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008, 31(9):454-463.
12. Bharadwaj P.R., Bates K.A. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases. Transl. Psychiatry 2013, 3:e332.
13. Bharadwaj P.R., Verdile G. Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Abeta42 levels in yeast. J. Alzheimers Dis. 2012, 32(4):949-967.
14. Bhat R.V., Budd Haeberlein S.L., et al. Glycogen synthase kinase 3: a drug target for CNS therapies. J. Neurochem. 2004, 89(6):1313-1317.
15. Boddapati S., Levites Y., et al. Inhibiting beta-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP. J. Mol. Biol. 2011, 405(2):436-447.
16. Bolognesi M.L., Bartolini M., et al. Bis(7)-tacrine derivatives as multitarget-directed ligands: focus on anticholinesterase and antiamyloid activities. ChemMedChem 2010, 5(8):1215-1220.
17. Bonda D.J., Lee H.G., et al. Role of metal dyshomeostasis in Alzheimer's disease. Metallomics 2011, 3(3):267-270.
18. Brimijoin S. Molecular forms of acetylcholinesterase in brain, nerve and muscle: nature, localization and dynamics. Prog. Neurobiol. 1983, 21(4):291-322.
19. Brodaty H., Breteler M.M., et al. The world of dementia beyond 2020. J. Am. Geriatr. Soc. 2011, 59(5):923-927.
20. Brodney M.A., Auperin D.D., et al. Diamide amino-imidazoles: a novel series of gamma-secretase inhibitors for the treatment of Alzheimer's disease. Bioorg. Med. Chem. Lett. 2011, 21(9):2631-2636.
21. Burgess S., Geddes J., et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst. Rev. 2001, CD003013.
22. Caccamo A., Majumder S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J. Biol. Chem. 2010, 285(17):13107-13120.
23. Camps P., El Achab R., et al. New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. J. Med. Chem. 2000, 43(24):4657-4666.
24. Camps P., Formosa X., et al. Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. J. Med. Chem. 2008, 51(12):3588-3598.
25. Cano-Cuenca N., Solis-Garcia del Pozo J.E., et al. Evidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysis. J. Alzheimers Dis. 2014, 38(1):155-164.
26. Cavallucci V., D'Amelio M. Matter of life and death: the pharmacological approaches targeting apoptosis in brain diseases. Curr. Pharm. Des. 2011, 17(3):215-229.
27. Chalecka-Franaszek E., Chuang D.M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. U.S.A. 1999, 96(15):8745-8750.
28. Chang W.P., Huang X., et al. Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J. 2011, 25(2):775-784.
29. Chao X., He X., et al. Bioorg. Med. Chem. Lett. 2012, 22(20):6498-6502.
30. Charvet C., Wissler M., et al. Phosphorylation of Tip60 by GSK-3 determines the induction of PUMA and apoptosis by p53. Mol. Cell 2011, 42(5):584-596.
31. Chen Q., Cui W., et al. Studying the mechanism that enables paullones to selectively inhibit glycogen synthase kinase 3 rather than cyclin-dependent kinase 5 by molecular dynamics simulations and free-energy calculations. J. Mol. Model. 2011, 17(4):795-803.
32. Choi Y., Kim H.S., et al. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 2007, 32(11):2393-2404.
33. Clevers H., Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012, 149(6):1192-1205.
34. Coghlan M.P., Culbert A.A., et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 2000, 7(10):793-803.
35. Craig L.A., Hong N.S., et al. Revisiting the cholinergic hypothesis in the development of Alzheimer's disease. Neurosci. Biobehav. Rev. 2011, 35(6):1397-1409.
36. Cross D.A., Culbert A.A., et al. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J. Neurochem. 2001, 77(1):94-102.
37. de Almeida J.P., Saldanha C. Nonneuronal cholinergic system in human erythrocytes: biological role and clinical relevance. J. Membr. Biol. 2010, 234(3):227-234.
38. De Strooper B., Vassar R., et al. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 2010, 6(2):99-107.
39. De Zoysa M. Medicinal benefits of marine invertebrates: sources for discovering natural drug candidates. Adv. Food Nutr. Res. 2012, 65:153-169.
40. Del Ser T., Steinwachs K.C., et al. Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. J. Alzheimers Dis. 2013, 33(1):205-215.
41. Desire L., Marcade M., et al. Clinical trials of EHT 0202, a neuroprotective and procognitive alpha-secretase stimulator for Alzheimer's disease. Alzheimers Dement. 2009, 5(4):255-256.
42. Ding H., Matthews T.A., et al. Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation. J. Biol. Chem. 2006, 281(28):19107-19114.
43. Dominguez J.M., Fuertes A., et al. Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J. Biol. Chem. 2012, 287(2):893-904.
44. Donmez G. The neurobiology of sirtuins and their role in neurodegeneration. Trends Pharmacol. Sci. 2012, 33(9):494-501.
45. Dovey H.F., John V., et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 2001, 76(1):173-181.
46. Dvir H., Silman I., et al. Acetylcholinesterase: from 3D structure to function. Chem. Biol. Interact. 2010, 187(1-3):10-22.
47. Elmore S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 2007, 35(4):495-516.
48. Endres K., Fahrenholz F. Regulation of alpha-secretase ADAM10 expression and activity. Exp. Brain Res. 2012, 217(3-4):343-352.
49. Espinosa L., Ingles-Esteve J., et al. Phosphorylation by glycogen synthase kinase-3 beta down-regulates Notch activity, a link for Notch and Wnt pathways. J. Biol. Chem. 2003, 278(34):32227-32235.
50. Etcheberrigaray R., Tan M., et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(30):11141-11146.
51. Evans D.A., Funkenstein H.H., et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. J. Am. Med. Assoc. 1989, 262(18):2551-2556.
52. Feng S., Wang Z., et al. Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J. Med. Chem. 2005, 48(3):655-657.
53. Ferri C.P., Prince M., et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366(9503):2112-2117.
54. Finnin M.S., Donigian J.R., et al. Structure of the histone deacetylase SIRT2. Nat. Struct. Biol. 2001, 8(7):621-625.
55. Foltz D.R., Santiago M.C., et al. Glycogen synthase kinase-3beta modulates notch signaling and stability. Curr. Biol. 2002, 12(12):1006-1011.
56. Fonseca A.C., Resende R., et al. Cholesterol and statins in Alzheimer's disease: current controversies. Exp. Neurol. 2010, 223(2):282-293.
57. Forlenza O.V., Diniz B.S., et al. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br. J. Psychiatry 2011, 198(5):351-356.
58. Francis P.T., Palmer A.M., et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 1999, 66(2):137-147.
59. Frank B., Gupta S. A review of antioxidants and Alzheimer's disease. Ann. Clin. Psychiatry 2005, 17(4):269-286.
60. Freitag M., Schemies J., et al. Synthesis and biological activity of splitomicin analogs targeted at human NAD(+)-dependent histone deacetylases (sirtuins). Bioorg. Med. Chem. 2011, 19(12):3669-3677.
61. Friden-Saxin M., Seifert T., et al. Synthesis and evaluation of substituted chroman-4-one and chromone derivatives as sirtuin 2-selective inhibitors. J. Med. Chem. 2012, 55(16):7104-7113.
62. Galdeano C., Viayna E., et al. Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases. J. Med. Chem. 2012, 55(2):661-669.
63. Gamblin T.C., Chen F., et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(17):10032-10037.
64. Gao C., Holscher C., et al. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev. Neurosci. 2012, 23(1):1-11.
65. Gastard M.C., Troncoso J.C., et al. Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann. Neurol. 2003, 54(3):393-398.
66. Ghosh A.K., Brindisi M., et al. Developing beta-secretase inhibitors for treatment of Alzheimer's disease. J. Neurochem. 2012, 120(1):71-83.
67. Ghosh A.K., Gemma S., et al. β-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics 2008, 5(3):399-408.
68. Goedert M., Spillantini M.G. A century of Alzheimer's disease. Science 2006, 314(5800):777-781.
69. Gould T.D., Chen G., et al. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 2004, 29(1):32-38.
70. Gould T.D., Manji H.K. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005, 30(7):1223-1237.
71. Greig N.H., Lahiri D.K., et al. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int. Psychogeriatr. 2002, 14(1):77-91.
72. Guan J.S., Haggarty S.J., et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009, 459(7243):55-60.
73. Guillozet-Bongaarts A.L., Garcia-Sierra F., et al. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol. Aging 2005, 26(7):1015-1022.
74. Guo H., Albrecht S., et al. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. Am. J. Pathol. 2004, 165(2):523-531.
75. Haigis M.C., Sinclair D.A. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 2010, 5:253-295.
76. Hamann M., Alonso D., et al. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. J. Nat. Prod. 2007, 70(9):1397-1405.
77. Hampel H., Ewers M., et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J. Clin. Psychiatry 2009, 70(6):922-931.
78. Han J. Traditional Chinese medicine and the search for new antineoplastic drugs. J. Ethnopharmacol. 1988, 24(1):1-17.
79. Hanger D.P., Betts J.C., et al. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 1998, 71(6):2465-2476.
80. He C., Klionsky D.J. Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 2009, 43(1):67-93.
81. Heller M., Hanahan D.J. Human erythrocyte membrane bound enzyme acetylcholinesterase. Biochim. Biophys. Acta 1972, 255(1):251-272.
82. Hernandez F., Gomez de Barreda E., et al. GSK3: a possible link between beta amyloid peptide and tau protein. Exp. Neurol. 2010, 223(2):322-325.
83. Hoeflich K.P., Luo J., et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000, 406(6791):86-90.
84. Hong L., Koelsch G., et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 2000, 290(5489):150-153.
85. Hooper C., Killick R., et al. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 2008, 104(6):1433-1439.
86. Hooper N.M., Turner A.J. The search for α-secretase and its potential as a therapeutic approach to Alzheimer's disease. Curr. Med. Chem. 2002, 9(11):1107-1119.
87. Hopkins C.R. ACS chemical neuroscience molecule spotlight on begacestat (GSI-953). Chem. Neurosci. 2012, 3(1):3-4.
88. Hu S., Begum A.N., et al. GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol. Dis. 2009, 33(2):193-206.
89. Huang L., Luo Z., et al. Berberine derivatives, with substituted amino groups linked at the 9-position, as inhibitors of acetylcholinesterase/butyrylcholinesterase. Bioorg. Med. Chem. Lett. 2010, 20(22):6649-6652.
90. Hughes C.P., Berg L., et al. A new clinical scale for the staging of dementia. Br. J. Psychiatry 1982, 140:566-572.
91. Huhtiniemi T., Salo H.S., et al. Structure-based design of pseudopeptidic inhibitors for SIRT1 and SIRT2. J. Med. Chem. 2011, 54(19):6456-6468.
92. Hur E.M., Zhou F.Q. GSK3 signalling in neural development. Nat. Rev. Neurosci. 2010, 11(8):539-551.
93. Hussain I., Hawkins J., et al. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J. Neurochem. 2007, 100(3):802-809.
94. Imanshahidi M., Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother. Res. 2008, 22(8):999-1012.
95. Imbimbo B.P. Alzheimer's disease: γ-secretase inhibitors. Drug Discovery Today 2008, 5(3):169-175.
96. Inestrosa N.C., Alvarez A., et al. Acetylcholinesterase accelerates assembly of amyloi beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996, 16(4):881-891.
97. Iserloh U., Pan J., et al. Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor. Bioorg. Med. Chem. Lett. 2008, 18(1):418-422.
98. Jiang T., Yu J.T., et al. Temsirolimus promotes autophagic clearance of amyloid-beta and provides protective effects in cellular and animal models of Alzheimer's disease. Pharmacol. Res. 2014, 81:54-63.
99. Johnson T.A., Sohn J., et al. Natural product libraries to accelerate the high-throughput discovery of therapeutic leads. J. Nat. Prod. 2011, 74(12):2545-2555.
100. Jung H.A., Min B.S., et al. Anti-Alzheimer and antioxidant activities of Coptidis Rhizoma alkaloids. Biol. Pharm. Bull. 2009, 32(8):1433-1438.
101. Kaidanovich-Beilin O., Woodgett J.R. GSK-3: functional insights from cell biology and animal models. Front. Mol. Neurosci. 2011, 4:40.
102. Kamphuis P.J., Verhey F.R., et al. Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial. J. Nutr. Health Aging 2011, 15(8):720-724.
103. Kang R., Zeh H.J., et al. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011, 18(4):571-580.
104. Kessing L.V., Forman J.L., et al. Does lithium protect against dementia?. Bipolar Disord. 2010, 12(1):87-94.
105. Kessing L.V., Sondergard L., et al. Lithium treatment and risk of dementia. Arch. Gen. Psychiatry 2008, 65(11):1331-1335.
106. Kim H.S., Suh Y.H. Minocycline and neurodegenerative diseases. Behav. Brain Res. 2009, 196(2):168-179.
107. Kim J., Kundu M., et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011, 13(2):132-141.
108. Kim W.Y., Snider W.D. Functions of GSK-3 signaling in development of the nervous system. Front. Mol. Neurosci. 2011, 4:44.
109. Kim W.Y., Wang X., et al. GSK-3 is a master regulator of neural progenitor homeostasis. Nat. Neurosci. 2009, 12(11):1390-1397.
110. Kim D.H., Sarbassov D.D., et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110(2):163-175.
111. Kirby L.A., Schott J.T., et al. Glycogen synthase kinase 3 (GSK3) inhibitor, SB-216763, promotes pluripotency in mouse embryonic stem cells. PLoS ONE 2012, 7(6):e39329.
112. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U.S.A. 1996, 93(16):8455-8459.
113. Koo E.H., Kopan R. Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. Nat. Med. 2004, 10:26-33.
114. Kulkarni S.K., Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother. Res. 2010, 24(3):317-324.
115. Kwitkowski V.E., Prowell T.M., et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010, 15(4):428-435.
116. Kwon H.B., Kozorovitskiy Y., et al. Neuroligin-1-dependent competition regulates cortical synaptogenesis and synapse number. Nat. Neurosci. 2012, 15(12):1667-1674.
117. Lane R.M., Kivipelto M., et al. Acetylcholinesterase and its inhibition in Alzheimer disease. Clin. Neuropharmacol. 2004, 27(3):141-149.
118. Lane R.M., Potkin S.G., et al. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int. J. Neuropsychopharmacol. 2006, 9(1):101-124.
119. Lange C., Mix E., et al. Small molecule GSK-3 inhibitors increase neurogenesis of human neural progenitor cells. Neurosci. Lett. 2011, 488(1):36-40.
120. Lanz T.A., Himes C.S., et al. The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J. Pharmacol. Exp. Ther. 2003, 305(3):864-871.
121. Lara E., Mai A., et al. Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 2009, 28(6):781-791.
122. Larson E.B., Kukull W.A., et al. Cognitive impairment: dementia and Alzheimer's disease. Annu. Rev. Public Health 1992, 13:431-449.
123. Lavu S., Boss O., et al. Sirtuins - novel therapeutic targets to treat age-associated diseases. Nat. Rev. Drug Discov. 2008, 7(10):841-853.
124. Leclerc S., Garnier M., et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?. J. Biol. Chem. 2001, 276(1):251-260.
125. Leost M., Schultz C., et al. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 2000, 267(19):5983-5994.
126. Leyhe T., Eschweiler G.W., et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J. Alzheimers Dis. 2009, 16(3.):649-656.
127. Li J., Hu J., et al. Protection of PMS777, a new AChE inhibitor with PAF antagonism, against amyloid-beta-induced neuronal apoptosis and neuroinflammation. Cell. Mol. Neurobiol. 2009, 29(4):589-595.
128. Li J., Huang H., et al. Pharmacological profile of PMS777, a new AChE inhibitor with PAF antagonistic activity. Int. J. Neuropsychopharmacol. 2007, 10(1):21-29.
129. Li J., Wu H.M., et al. Huperzine A for Alzheimer's disease. Cochrane Database Syst. Rev. 2008, CD005592.
130. Li L., Zhang S., et al. Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-beta pathology in a mouse model of Alzheimer's disease. Curr. Alzheimer Res. 2013, 10(4):433-441.
131. Li M., Ona V.O., et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000, 288(5464):335-339.
132. Li W., Mak M., et al. Novel anti-Alzheimer's dimer Bis(7)-cognitin: cellular and molecular mechanisms of neuroprotection through multiple targets. Neurotherapeutics 2009, 6(1):187-201.
133. Li X., Alafuzoff I., et al. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J. 2005, 272(16):4211-4220.
134. Luna-Medina R., Cortes-Canteli M., et al. NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J. Neurosci. 2007, 27(21):5766-5776.
135. Luo X., Yan R. Inhibition of BACE1 for therapeutic use in Alzheimer's disease. Int. J. Clin. Exp. Pathol. 2010, 3(6):618-628.
136. Mandelkow E.M., Biernat J., et al. Tau domains, phosphorylation, and interactions with microtubules. Neurobiol. Aging 1995, 16(3):355-362.
137. Mangialasche F., Solomon A., et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010, 9(7):702-716.
138. Marcade M., Bourdin J., et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J. Neurochem. 2008, 106(1):392-404.
139. Marco-Contelles J., Leon R., et al. Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease. J. Med. Chem. 2009, 52(9):2724-2732.
140. Martin L., Latypova X., et al. Tau protein kinases: involvement in Alzheimer's disease. Ageing Res. Rev. 2013, 12(1):289-309.
141. Martin L., Magnaudeix A., et al. The new indirubin derivative inhibitors of glycogen synthase kinase-3,6-BIDECO and 6-BIMYEO, prevent tau phosphorylation and apoptosis induced by the inhibition of protein phosphatase-2A by okadaic acid in cultured neurons. J. Neurosci. Res. 2011, 89(11):1802-1811.
142. Martinez A., Alonso M., et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 2002, 45(6):1292-1299.
143. Martinez A., Castro A., et al. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 2002, 22(4):373-384.
144. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430(7000):631-639.
145. Maxwell M.M., Tomkinson E.M., et al. The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Hum. Mol. Genet. 2011, 20(20):3986-3996.
146. McKhann G., Drachman D., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34(7):939-944.
147. Medda F., Russell R.J., et al. Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J. Med. Chem. 2009, 52(9):2673-2682.
148. Medina M., Wandosell F. Deconstructing GSK-3: the fine regulation of its activity. Int. J. Alzheimers Dis. 2011, 2011:479249.
149. Meijer L., Skaltsounis A.L., et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. 2003, 10(12):1255-1266.
150. Mehta M., Adem A., et al. New acetylcholinesterase inhibitors for Alzheimer's disease. Int. J. Alzheimers Dis. 2012, 2012:728983.
151. Meijer L., Thunnissen A.M., et al. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 2000, 7(1):51-63.
152. Mendes C.T., Mury F.B., et al. Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259(1):16-22.
153. Minati L., Edginton T., et al. Current concepts in Alzheimer's disease: a multidisciplinary review. Am. J. Alzheimers Dis. Other Demen. 2009, 24(2):95-121.
154. Mirlashari M.R., Randen I., et al. Glycogen synthase kinase-3 (GSK-3) inhibition induces apoptosis in leukemic cells through mitochondria-dependent pathway. Leuk. Res. 2012, 36(4):499-508.
155. Mischak R. Apoptosis ICN/ESP Caspase inhibitors applications in vivo and in vitro. ICN Bioconcepts 2002, 8:1-5.
156. Monczor M. Diagnosis and treatment of Alzheimer's disease. Curr. Med. Chem. - Central Nervous Syst. Agents 2005, 5:5-13.
157. Mukai F., Ishiguro K., et al. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J. Neurochem. 2002, 81(5):1073-1083.
158. Munoz-Ruiz P., Rubio L., et al. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. J. Med. Chem. 2005, 48(23):7223-7233.
159. Napper A.D., Hixon J., et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J. Med. Chem. 2005, 48(25):8045-8054.
160. Neugebauer R.C., Uchiechowska U., et al. Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. J. Med. Chem. 2008, 51(5):1203-1213.
161. Nixon R.A. The role of autophagy in neurodegenerative disease. Nat. Med. 2013, 19(8):983-997.
162. Nunes P.V., Forlenza O.V., et al. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br. J. Psychiatry 2007, 190:359-360.
163. Outeiro T.F., Kontopoulos E., et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007, 317(5837):516-519.
164. Paccalin M., Pain-Barc S. Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2006, 22(4):320-326.
165. Pang Y.P., Quiram P., et al. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J. Biol. Chem. 1996, 271(39):23646-23649.
166. Pesnot T., Kempter J., et al. Two-step synthesis of novel, bioactive derivatives of the ubiquitous cofactor nicotinamide adenine dinucleotide (NAD). J. Med. Chem. 2011, 54(10):3492-3499.
167. Petit-Paitel A., Brau F., et al. Involvement of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons. PLoS ONE 2009, 4(5):e5491.
168. Phiel C.J., Wilson C.A., et al. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423(6938):435-439.
169. Pi R., Mao X., et al. Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-beta-mediated Alzheimer's disease-associated pathogenesis in vitro and in vivo. PLoS ONE 2012, 7(2):e31921.
170. Pickford F., Masliah E. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J. Clin. Invest. 2008, 118(6):2190-2199.
171. Portelius E., Van Broeck B., et al. Acute effect on the Abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs. J. Alzheimer's Dis. 2010, 21(3):1005-1012.
172. Pratico D. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol. Sci. 2008, 29(12):609-615.
173. Rayasam G.V., Tulasi V.K., et al. Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol. 2009, 56(6):885-898.
174. Rees T.M., Brimijoin S. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Drugs Today 2003, 39(1):75-83.
175. Roach P.J., Depaoli-Roach A.A., et al. Glycogen and its metabolism: some new developments and old themes. Biochem. J. 2012, 441(3):763-787.
176. Rockenstein E., Torrance M., et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J. Neurosci. 2007, 27(8):1981-1991.
177. Rohn T.T., Head E. Caspases as therapeutic targets in Alzheimer's disease: is it time to cut to the chase?. Int. J. Clin. Exp. Pathol. 2009, 2(2):108-118.
178. Rohn T.T., Kokoulina P., et al. Caspase activation in transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh. Int. J. Clin. Exp. Med. 2009, 2(4):300-308.
179. Rohn T.T., Rissman R.A., et al. Caspasea activation in the Alzheimer's disease brain: tortuous and torturous. Drug News Perspect. 2002, 15(9):549-557.
180. Sadqi M., Hernandez F., et al. Alpha-helix structure in Alzheimer's disease aggregates of tau-protein. Biochemistry. 2002, 41(22):7150-7155.
181. Sanchez J.F., Sniderhan L.F., et al. Glycogen synthase kinase 3beta-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappa B signaling. Mol. Cell. Biol. 2003, 23(13):4649-4662.
182. Sarkar S., Rubinsztein D.C. Small molecule enhancers of autophagy for neurodegenerative diseases. Mol. Biosyst. 2008, 4(9):895-901.
183. Sarkar S., Floto R.A. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 2005, 170(7):1101-1111.
184. Sarkar S., Perlstein E.O., et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol. 2007, 3(6):331-338.
185. Sathya M., Premkumar P., et al. BACE1 in Alzheimer's disease. Clin. Chim. Acta 2012, 414C:171-178.
186. Sauve A.A., Wolberger C., et al. The biochemistry of sirtuins. Annu. Rev. Biochem. 2006, 75:435-465.
187. Scheltens P., Kamphuis P.J. Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. Alzheimers Dement. 2010, 6(1):1-10. e11.
188. Schliebs R., Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J. Neural Transm. 2006, 113(11):1625-1644.
189. Schliebs R., Arendt T. The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 2011, 221(2):555-563.
190. Schmidt R., Neff F., et al. Therapy of Alzheimer's disease: current status and future development. Neuropsychiatrie 2008, 22(3):153-171.
191. Schmitt B., Bernhardt T., et al. Combination therapy in Alzheimer's disease: a review of current evidence. CNS drugs. 2004, 18(13):827-844.
192. Sereno L., Coma M., et al. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol. Dis. 2009, 35(3):359-367.
193. Shah R.C., Kamphuis P.J., et al. The S-connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. Alzheimers Res. Ther. 2013, 5(6):59.
194. Shi A., Huang L., et al. Synthesis, biological evaluation and molecular modeling of novel triazole-containing berberine derivatives as acetylcholinesterase and beta-amyloid aggregation inhibitors. Bioorg. Med. Chem. 2011, 19(7):2298-2305.
195. Shi P., Scott M.A., et al. Synapse microarray identification of small molecules that enhance synaptogenesis. Nat. Commun. 2011, 2:510.
196. Shi Y.F., Zhang H.Y., et al. Novel 16-substituted bifunctional derivatives of huperzine B: multifunctional cholinesterase inhibitors. Acta Pharmacol. Sin. 2009, 30(8):1195-1203.
197. Silman I., Sussman J.L. Acetylcholinesterase: how is structure related to function?. Chem. Biol. Interact. 2008, 175:3-10.
198. Sirerol-Piquer M., Gomez-Ramos P., et al. GSK3beta overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. Hippocampus 2011, 21(8):910-922.
199. Smith D.G., Buffet M., et al. 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 2001, 11(5):635-639.
200. Snow A.D., Cummings J., et al. Exebryl-1: a novel small molecule currently in human clinical trials as a disease-modifying drug for the treatment of Alzheimer's disease. Alzheimer's Dement. 2009, 5(4):418.
201. Son J.H., Shim J.H., et al. Neuronal autophagy and neurodegenerative diseases. Exp. Mol. Med. 2012, 44(2):89-98.
202. Spilman P., Podlutskaya N. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS ONE 2010, 5(4):e9979.
203. St George-Hyslop P.H. Piecing together Alzheimer's. Sci. Am. 2000, 283(6):76-83.
204. Stambolic V., Ruel L., et al. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. 1996, 6(12):1664-1668.
205. ®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy 2013, 9(4):617-618.
206. Stockley J.H., Ravid R., et al. Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain. FEBS Lett. 2006, 580:6550-6560.
207. Sudhof T.C. Neuroligins and neurexins link synaptic function to cognitive disease. Nature 2008, 455(7215):903-911.
208. Sussman J.L., Harel M., et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991, 253(5022):872-879.
209. Suzuki T., Khan M.N., et al. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors. J. Med. Chem. 2012, 55(12):5760-5773.
210. Takahashi-Yanaga F., Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell. Signal. 2008, 20(4):581-589.
211. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J. Alzheimer's Dis. 2006, 9:309-317.
212. Tan C.C., Yu J.T. Autophagy in aging and neurodegenerative diseases: implications for pathogenesis and therapy. Neurobiol. Aging 2014, 35(5):941-957.
213. Taylor D.M., Balabadra U., et al. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem. Biol. 2011, 6(6):540-546.
214. ter Haar E., Coll J.T., et al. Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat. Struct. Biol. 2001, 8(7):593-596.
215. Trapp J., Jochum A., et al. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J. Med. Chem. 2006, 49(25):7307-7316.
216. Trepanier C.H., Milgram N.W. Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy?. J. Alzheimer's Dis. 2010, 21(4):1089-1099.
217. Turner A.J., Fisk L., et al. Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration. Ann. N.Y. Acad. Sci. 2004, 1035:1-20.
218. Valvezan A.J., Klein P.S. GSK-3 and Wnt signaling in neurogenesis and bipolar disorder. Front. Mol. Neurosci 2012, 5:1.
219. Vassar R. Beta-secretase (BACE) as a drug target for Alzheimer's disease. Adv. Drug Deliv. Rev. 2002, 54(12):1589-1602.
220. Viscomi M.T., D'Amelio M. Stimulation of autophagy by rapamycin protects neurons from remote degeneration after acute focal brain damage. Autophagy 2012, 8(2):222-235.
221. Vougogiannopoulou K., Ferandin Y., et al. Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase-3 alter circadian period. J. Med. Chem. 2008, 51(20):6421-6431.
222. Waites C.L., Craig A.M., et al. Mechanisms of vertebrate synaptogenesis. Annu. Rev. Neurosci. 2005, 28:251-274.
223. Wang J., Wei Q., et al. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J. Biol. Chem. 2004, 279(19):19948-19954.
224. Wilkinson D.G., Francis P.T., et al. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004, 21(7):453-478.
225. Willem M., Lammich S., et al. Function, regulation and therapeutic properties of beta-secretase (BACE1). Semin. Cell Dev. Biol. 2009, 20(2):175-182.
226. Wolfe M.S. Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics 2008, 5(3):391-398.
227. Wollmer M.A. Cholesterol-related genes in Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801(8):762-773.
228. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990, 9(8):2431-2438.
229. Woodward M.C. Drug treatments in development for Alzheimer's disease. J. Pharm. Pract. Res. 2012, 42(1):58-65.
230. Xu J., Xiao N., et al. Thrombospondin 1 accelerates synaptogenesis in hippocampal neurons through neuroligin 1. Nat. Neurosci. 2010, 13(1):22-24.
231. Yan J., Sun L., et al. Rational design and synthesis of highly potent anti-acetylcholinesterase activity huperzine A derivatives. Bioorg. Med. Chem. 2009, 17(19):6937-6941.
232. Yang H.Q., Sun Z.K., et al. PMS777, a new cholinesterase inhibitor with anti-platelet activated factor activity, regulates amyloid precursor protein processing in vitro. Neurochem. Res. 2009, 34(3):528-535.
233. Yang Y., Chen S. Stimulation of autophagy prevents amyloid-beta peptide-induced neuritic degeneration in PC12 cells. J. Alzheimer's Dis. 2014, 8. (Epub ahead of print). 10.3233/JAD-132270.
234. Yin H., Kuret J. C-terminal truncation modulates both nucleation and extension phases of tau fibrillization. FEBS Lett. 2006, 580(1):211-215.
235. Zhang J., Zhu D., et al. BZYX, a novel acetylcholinesterase inhibitor, significantly improved chemicals-induced learning and memory impairments on rodents and protected PC12 cells from apoptosis induced by hydrogen peroxide. Eur. J. Pharmacol. 2009, 613(1-3):1-9.
236. Zhang N., Zhong R., et al. Structural features underlying selective inhibition of GSK3beta by dibromocantharelline: implications for rational drug design. Chem. Biol. Drug Des. 2011, 77(3):199-205.
237. Zhang Y., Au Q., et al. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity. Biochem. Biophys. Res. Commun. 2009, 386(4):729-733.
238. Zhu F., Qian C. Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. BMC Neurosci. 2006, 7:78.
239. Zhu S., Stavrovskaya I.G., et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002, 417(6884):74-78.
240. Zoghbi H.Y. Postnatal neurodevelopmental disorders: meeting at the synapse?. Science 2003, 302(5646):826-830.